Aim Diabetic kidney disease is one of the leading complications of Type 1 diabetes, but its prediction remains a challenge. We examined predictors of rapid decline in estimated GFR (eGFR) in two Type 1 diabetes cohorts: the Coronary Artery Calcification in Type 1 Diabetes (CACTI) and the Pittsburgh Epidemiology of Diabetes Complications (EDC).
Introduction
The public health burden of Type 1 diabetes, a disease affecting~30 million globally, is progressively increasing largely due to the prevalence of the associated vascular complications [1] [2] [3] . Diabetic kidney disease remains the leading cause of end-stage renal disease (ESRD) and dialysis in the USA [4] .
The appearance of albuminuria is usually the earliest clinical sign of diabetic kidney disease, but the paradigm of early diabetic kidney disease has evolved over the past decade based on the demonstration that microalbuminuria does not necessarily imply progressive decline in GFR in Type 1 diabetes [5] [6] [7] . The Diabetes Control and Complications Trial-Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) reported incident GFR < 60 ml/min/ 1.73 m 2 in 24% of people without prior microalbuminuria [8] . Therefore, rapid decline in GFR may be the most clinically relevant measure of diabetic kidney disease in Type 1 diabetes. Early renal function decline is defined as an annual loss ≥ 3 ml/min/1.73 m 2 , which represents a magnitude of change three times the rate of that expected in normal physiology (1 ml/min/1.73 m 2 /year), and corresponded to 25% of the cohort of the Cardiovascular Health Study, an observational study of risk factors for cardiovascular disease in adults 65 years or older, with the largest decline in GFR [9, 10] . We have previously demonstrated that early renal function decline is associated with both hyperfiltration and incident eGFR < 60 ml/min/1.73 m 2 [11] . The determinants of early renal function decline remain unclear in Type 1 diabetes. We thus conducted parallel analyses in two large Type 1 diabetes cohorts, the Coronary Artery Calcification in Type 1 diabetes (CACTI) and the Pittsburgh Epidemiology of Diabetes Complications (EDC) studies, to examine predictors of early renal function decline.
Materials and Methods

CACTI
The CACTI study enrolled 1416 participants, aged 19-56 years old; 652 with and 764 without Type 1 diabetes, who were asymptomatic for cardiovascular disease (CVD) at the baseline visit in 2000-2002 and were re-examined 6.2 AE 0.5 years later (n = 1173), as described previously [12] . Only CACTI participants diagnosed between 1965 and 1980, before 17 years of age and who had Type 1 diabetes for at least 7 years at the baseline assessment with serum creatinine < 2 mg/dl at baseline visit were included in the parallel analyses. To distinguish between early renal function decline and physiological age-related GFR decline, we excluded participants who had an annual GFR decline between 1 and 3 ml/min/1.73 m 2 , which gave a total of 142 participants with longitudinal data (Fig. 1) . The study was approved by the Colorado Multiple Institutional Review Board and all participants provided informed consent.
We measured height and weight, and calculated BMI in kg/ m 2 . Resting systolic blood pressure (SBP) and fifth-phase diastolic blood pressure (DBP) were measured three times while the patient was seated, and the second and third measurements were averaged for subsequent analysis. After an overnight fast, blood was collected, centrifuged and separated. Plasma was stored at 4°C until assayed. Total plasma cholesterol and triglyceride levels were measured using standard enzymatic methods; HDL cholesterol was separated using dextran sulphate, and LDL cholesterol was calculated using the Friedewald formula. High-performance liquid chromatography was used to measure HbA 1c (HPLC, BioRad variant). Two timed overnight urine samples were collected in duplicate and urine creatinine and albumin were measured (RIA, Diagnostic Products) and averaged. At both visits, urinary albumin excretion rate (AER) and albumin-tocreatinine ratio (ACR) were measured. GFR (ml/min/ 1.73 m 2 ) was determined using the CKD-EPI creatinine equation [13] . (Fig. 1) . Before attending each cycle of examinations, information was collected by questionnaire concerning demographic characteristics, medical history and healthcare behaviours, as described previously [15] . At each cycle, both a standardized medical history and clinical examination were performed to document complications of diabetes. Blood pressure was measured by a random-zero sphygmomanometer according to a standardized protocol [16] after a 5-min rest period. Blood pressure was analysed, using the mean of the second and third readings. Participants on blood pressure medication or with a blood pressure > 140/90 mm Hg were classified as hypertensive.
Fasting blood samples were assayed for lipids, lipoproteins and HbA 1c . HDL cholesterol was determined by a heparin and manganese procedure, a modification of the Lipid What's new?
• Early renal function decline is increasingly recognized as an intermediate phenotype of diabetic kidney disease.
• In this parallel analysis in the Coronary Artery Calcification in Type 1 Diabetes (CACTI) and Pittsburgh Epidemiology of Diabetes Complications (EDC) studies, baseline estimated GFR and albuminuria were the strongest predictors of early renal function decline.
ª 2017 Diabetes UK Research Clinics method [15] . Cholesterol was measured enzymatically, as were triglycerides, as described previously [15] . LDL cholesterol levels were calculated from measurements of the levels of total cholesterol, triglycerides and HDL cholesterol [17] . Albuminuria determined by urine AER from at least two of three timed urine collections (24-h, overnight, random timed post clinic). Urinary albumin was determined immunonephelometrically [15] , and creatinine was assayed using an Ectachem 400 analyser (Eastman Kodak, Rochester, NY, USA). GFR (ml/min/1.73 m 2 ) was determined using CKD-EPI creatinine equation [13] .
Diabetic kidney disease
Albuminuria was defined as AER ≥ 20 lg/min if timed urine samples were obtained, or ACR ≥ 30 mg/g (3.4 mg/mmol) for spot samples if AER was unavailable. Macroalbuminuria was defined as AER ≥ 200 lg/min or ACR ≥ 300 mg/g (34 mg/mmol) for spot samples if AER was unavailable. For the parallel analyses, we used eGFR data at baseline and follow-up and calculated the difference in eGFR between the two visits (ΔeGFR). The annual change in eGFR was calculated by dividing ΔeGFR by the time (years) between the two visits. Early renal function decline was defined as an annual GFR loss ≥ 3 ml/min/1.73 m 2 vs. the expected agerelated decline of ≤ 1 ml/min/1.73 m 2 /year [11, 18] . Chronic kidney disease (CKD) was defined as eGFR < 60 ml/min/ 1.73 m 2 . End-stage renal disease (ESRD) was defined as kidney transplantation, needing dialysis or GFR < 15 ml/ min/1.73 m 2 .
Statistical analysis
Parallel analyses were performed in EDC and CACTI. Analyses were performed in SAS (v. 9.4 for Windows; SAS Institute, Cary, NC, USA). Differences between participants with and without early renal function decline were assessed using the chi-squared or Fisher's exact test, as appropriate, for categorical variables and the t-test for continuous variables. Positively skewed variables (ACR) were natural log transformed. Univariable and multivariable logistic regression models were built to examine the associations between variables at baseline and the development of early renal function decline. Variables considered for inclusion in the multivariable models were based on a priori criteria: significance in previous work, significant contribution to the model (P < 0.1), or confounding between the main variable of interest and the outcome by > 10%. The following models were built: model 1 (eGFR, log ACR, sex), model 2 (model 1 + HbA 1c , duration and BMI) and model 3 (model 2 + hypertension, ACEi use and LDL-C). Finally, model 3 (without sex as a covariate) was re-run stratifying by sex to examine sex-specific determinants of early renal function 
Results
Baseline characteristics
Baseline characteristics for this parallel analysis in CACTI and EDC are shown in Table 1 . Although participants of the two cohorts were similar in regards to age at diagnosis, duration, BMI and blood pressure, there was a higher percentage of males in EDC. On average, EDC participants had worse lipid profiles, glycaemic control and a lower use of ACE inhibition (Table 1) . Tables S1 and S2 show baseline characteristics of participants in the subcohorts of CACTI and EDC used for the parallel analyses compared to the entire cohort.
Diabetic kidney disease
The prevalence of microalbuminuria or greater at baseline was 17% in CACTI and 57% in EDC. Similarly, the prevalence of macroalbuminuria was 4% in CACTI and 22% in EDC. The incidence of microalbuminuria or greater was 3% in CACTI and 12% in EDC, and the incidence for macroalbuminuria was 1% in CACTI and 5% in EDC. The incidence of impaired GFR was 4% in CACTI and 10% in EDC. Only one participant in EDC developed ESRD. Conversely, no participants in CACTI had incident ESRD. The incidence of early renal function decline was 36% in CACTI and 41% in EDC.
Early renal function decline in CACTI and EDC
Participants who experienced early renal function decline in CACTI had greater eGFR at baseline (118 AE 18 vs. 93 AE 21 ml/min/1.73 m 2 , P < 0.0001) and a higher prevalence of macroalbuminuria at baseline (11.1% vs. 0.0%, P = 0.005). No difference was observed for sex, ethnicity, age at diagnosis, glycaemic control, BMI or lipid profiles (Table 2) .
Participants who experienced early renal function decline in EDC had worse glycaemic control (76 AE 15 vs. 64 AE 11 mmol/mol, P < 0.0001), higher total cholesterol (5.2 AE 1.1 vs. 4.7 AE 1.0 mmol/l, P = 0.03) and triglyceride concentrations (1.2 AE 0.2 vs. 0.9 AE 0.2 mmol/l, P = 0.006), and greater eGFR at baseline (107 AE 21 vs. 94 AE 22 ml/min/ 1.73 m 2 , P = 0.004) than those who did not experience early renal function decline. No difference was observed for sex, ethnicity, age at diagnosis, BMI, LDL-C or HDL-C (Table 2) . 10 of 142 (7) 6 of 95 (6) Values in parentheses are percentages. *Geometric mean and SD of the geometric mean reported. † Median, P25-75.
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Predictors of early renal function decline in CACTI and EDC
As shown in the < 52 mmol/mol, 52 to < 60 mmol/mol, 60 to < 69 mmol/ mol, ≥ 69 mmol/mol; EDC: < 57 mmol/mol, 57 to < 68 mmo/mol, 68 to < 76 mmol/mol, ≥ 76 mmol/mol), there was a trend towards greater incidence of early renal function decline across the HbA 1c categories for EDC (P < 0.0001), but not CACTI (P = 0.57) (Fig. 2) .
Discussion
Although participants of CACTI and EDC were similar in terms of age at diagnosis, diabetes duration and race/ ethnicity distribution, participants of the CACTI study had better glycaemic control and were more likely to use ACE inhibitors and hypertension medications than EDC participants. Despite these differences the incidence of early renal function decline was similar; 36% in CACTI and 41% in EDC, and baseline eGFR and ACR were strong predictors of early renal function decline in both cohorts. Use of ACE inhibitor treatment inversely predicted early renal function decline in women with Type 1 diabetes in the CACTI cohort. Finally, in stepwise selection models in EDC, HbA 1c was also associated with greater odds of early renal function decline.
Early renal function decline is increasingly recognized as an early intermediate phenotype of diabetic kidney disease. GFR is hypothesized to fall progressively after renal hyperfiltration and may lead, in the long run, to ESRD [19] . GFR declines with age and an annual loss of~1 ml/min/1.73 m 2 is described in studies of normal aging [20] . The cut-off for annual GFR of ≥ 3 ml/min/1.73 m 2 distinguishes early renal function decline from slow changes in GFR associated with aging or changes in hydration status, and is beyond the range of measurement noise expected in estimating GFR [9] . We have previously demonstrated in CACTI that early renal function decline is associated with both hyperfiltration and incident eGFR < 60 ml/min/1.73 m 2 [11] , but have not previously examined baseline predictors of early renal function decline in CACTI and EDC. Early renal function decline has also been shown to predict ESRD and cardiovascular outcomes in other cohorts [21, 22] . The mechanisms that initiate renal GFR decline in Type 1 diabetes remain controversial, but likely include both renal arteriolar and glomerular functional and structural defects due to hyperglycaemia, hypertension, dyslipidaemia and smoking. Also uncertain is whether those initial mechanisms remain operative as renal function decline progresses through advanced CKD stages. It is possible that early renal function decline (in the range of normal renal function) is related to functional changes, and that the late early renal function decline (CKD stage 3-5) is due to morphological injuries. However, data from the Joslin Kidney Study demonstrated similar rates of GFR loss during early and late phases of early renal function decline [23] , which may suggest similar underlying mechanisms.
In both CACTI and EDC, for every 10 ml/min/1.73 m 2 increase in baseline eGFR we observed a several fold increase in the odds of developing early renal function decline over time, which is consistent with our previous report demonstrating a relationship between hyperfiltration and early renal function decline [11] . Albuminuria at baseline was also associated with increased odds of early renal function decline in both cohorts. Early renal function decline is thought to be an intermediate high-risk phenotype of diabetic kidney disease, which may succeed hyperfiltration and albuminuria. Early renal function decline has also been shown to precede the onset of albuminuria in Type 1 diabetes [23] . HbA 1c at baseline was associated with early renal function decline in EDC in stepwise regression models, but not in CACTI, probably reflecting CACTI participants being in better glycaemic control. Beyond the known effects of ACE inhibition on hyperfiltration [24] , this study also demonstrated that ACE inhibition was associated with lower odds of early renal function decline in women in CACTI. This relationship was not evident in the EDC cohort, perhaps due to the low proportion of participants taking ACE inhibitors. It is recognized that compared with men, women have greater humoral, renal and systemic responsiveness of reninangiotensin-aldosterone system (RAAS) inhibition [25] . Furthermore, experimental data have also recently demonstrated that women with hyperfiltration have relatively higher efferent arteriolar resistance and lower renal blood flow compared with men with Type 1 diabetes and hyperfiltration [24] . Because RAAS inhibition acts primarily on the efferent arteriole, this could explain the greater RAAS inhibition response in women [26] . There are important limitations to this study, including the observational design and the absence of a direct measurement of GFR. A direct measure of GFR would have been too cumbersome for use in a large-scale clinical study like CACTI and EDC, and improved methods to detect early kidney changes are needed [27] . We employed the state-of-the-art CKD-EPI equations [13] , recently used by studies such as the DCCT-EDIC [28] , but it is established that eGFR at higher levels is associated with greater variability, which could lead to misclassification of hyperfiltration and normofiltration, and bias our study results to the null. We adjusted for a variety of important confounding variables, but cannot rule out the presence of unknown risk factors that may have biased or confounded the analyses. These subcohorts were created a priori to allow meaningful parallel analyses between CACTI and EDC. Therefore, results from these analyses may not be generalizable to people with Type 1 FIGURE 2 Early renal function decline incidence by HbA 1c categories.
(A) Incidence of early renal function decline by HbA 1c quartiles in CACTI < 52 mmol/mol, 52 to < 60 mmol/mol, 60 to < 69 mmol/mol, ≥ 69 mmol/mol. P-value for difference in incidence of early renal function decline across tertiles 0.64 (P-trend = 0.57). (B) Incidence of early renal function decline by HbA 1c quartiles in EDC < 57 mmol/ mol, 57 to < 68 mmol/mol, 68 to < 76 mmol/mol, ≥ 76 mmol/mol. P-value for difference in incidence of early renal function decline across tertiles 0.001 (P-trend < 0.0001).
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